WO2015027040A3 - Methods and compositions for treating schistosome infection - Google Patents

Methods and compositions for treating schistosome infection Download PDF

Info

Publication number
WO2015027040A3
WO2015027040A3 PCT/US2014/052049 US2014052049W WO2015027040A3 WO 2015027040 A3 WO2015027040 A3 WO 2015027040A3 US 2014052049 W US2014052049 W US 2014052049W WO 2015027040 A3 WO2015027040 A3 WO 2015027040A3
Authority
WO
WIPO (PCT)
Prior art keywords
schistosome
infection
methods
compositions
treating
Prior art date
Application number
PCT/US2014/052049
Other languages
French (fr)
Other versions
WO2015027040A2 (en
Inventor
Patrick SKELLY
Akram DA'DARAH
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2015027040A2 publication Critical patent/WO2015027040A2/en
Publication of WO2015027040A3 publication Critical patent/WO2015027040A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to compositions and methods for the treatment of Schistosome infection. In particular, the present invention provides therapeutic agents for the treatment of Schistosome infection. Embodiments of the present invention provide compositions, methods, and uses for treating or preventing infection by a schistosome (e.g., including but not limited to Schistosoma mansoni, Schistosoma haematobium, or Schistosoma japonicum), comprising administering 2-(2-fluorophenyl)ethyl] {3-methoxy-4-[2-oxo-2-(1 -piperidinyl)ethoxy]benzyl}amine hydrochloride to a subject infected with or at risk of infection by a schistosome. In some embodiments, the subject has been diagnosed with schistosome infection or lives in or is traveling to an area where schistosome infection is endemic.
PCT/US2014/052049 2013-08-21 2014-08-21 Methods and compositions for treating schistosome infection WO2015027040A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868394P 2013-08-21 2013-08-21
US61/868,394 2013-08-21

Publications (2)

Publication Number Publication Date
WO2015027040A2 WO2015027040A2 (en) 2015-02-26
WO2015027040A3 true WO2015027040A3 (en) 2015-08-06

Family

ID=52484265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/052049 WO2015027040A2 (en) 2013-08-21 2014-08-21 Methods and compositions for treating schistosome infection

Country Status (1)

Country Link
WO (1) WO2015027040A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209043B (en) * 2006-12-27 2011-08-10 长沙世唯科技有限公司 Application of sanguinarine or toddaline in prevention and cure of schistosomiasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209043B (en) * 2006-12-27 2011-08-10 长沙世唯科技有限公司 Application of sanguinarine or toddaline in prevention and cure of schistosomiasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARKER ET AL.: "The Possible Role of Acetylcholine in Schistosoma Mansoni.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 26, 1966, pages 656 - 665, XP055217918, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510701/pdf/bripharmchem00022-0149.pdf> *
DATABASE PUBCHEM 30 July 2005 (2005-07-30), XP055217926, accession no. 988459 *
SAYED ET AL.: "Identification of Oxadiazoles as New Drug Leads for the Control of Schistosomiasis.", NAT MED., vol. 14, no. 4, 2008, pages 407 - 412, XP002584558, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700043/pdf/nihms-90574.pdf> *

Also Published As

Publication number Publication date
WO2015027040A2 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AR121843A2 (en) OPHTHALMIC FORMULATION AND METHOD TO IMPROVE PRESBYOPIA
ATE502633T1 (en) CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
GEP201706786B (en) Methods and drug products for treating alzheimer&#39;s disease
EA201391670A1 (en) 1,3-oxazines as BACE1 and / or Bace2 inhibitors
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2013013692A (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors.
WO2011106573A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
PH12013502449A1 (en) Novel method for preventing or treating m tuberculosis infection
RU2014122858A (en) TREATMENT OF COGNITIVE DISORDERS (R) -7-CHLORO-N- (HINUKLIDIN-3-IL) BENZO [B] THIOPHEN-2-CARBOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
MX2013007558A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
BR112014006763A2 (en) n- (3- (2-amino-6,6-difluoro-4,4a, 5,6,7,7a-hexahydro-cyclopenta [e] [1,3] oxazin-4-yl) -phenyl) -amides as bace1 inhibitors
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
UA109459C2 (en) 5,6-Dihydroimidazo derivatives [1,2-a] Pyrazine-8-ylamine, Suitable as BACE-SECRETASE INHIBITORS (BACE)
MX2013007957A (en) 1,4 oxazines as bace1 and/or bace2 inhibitors.
HK1124546A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
BR112013020536A2 (en) 1,4-oxazepines as bace1 and / or bace2 inhibitors
WO2008090287A3 (en) Use of at least one botulism neurotoxin for treating the pain induced by therapeutic treatments for the aids virus
RU2013104381A (en) TREATMENT OF VASCULARIZED PIGMENT EPITELIUM EXTREMITATION THERAPY AGAINST VEGF
WO2015027040A3 (en) Methods and compositions for treating schistosome infection
RU2015114566A (en) HEPATITIS TREATMENT METHODS
FR3014693B1 (en) USE OF 3- (2-CHLORO-PHENYL) -1- [4- (4-FLUORO-BENZYL) -PIPERAZIN-1-YL] -PROPENONE FOR THE PREVENTION AND / OR TREATMENT OF PELVI-PERINEAL FUNCTIONAL PATHOLOGIES
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14837263

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14837263

Country of ref document: EP

Kind code of ref document: A2